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In the previous issue of Critical Care, Kamps and 
colleagues reported a surprising observation, one that at 
ﬁ rst glance contradicts perceived knowledge on thera-
peutic cooling [1]. Numerous studies have shown that 
hypo thermia can prevent or mitigate ischaemia/reper-
fusion injuries, and can be used to treat brain oedema 
[2-4]. Th ere is a grow ing list of potential indications, 
although many applica tions still await evaluation in 
rigorous clinical trials [4]. In recent years the mechanisms 
through which hypothermia provides tissue protection 
have been studied extensively [3]. One key mechanism is 
the inhibition of a harmful proinﬂ ammatory cascade that 
develops in injured organs following traumatic or 
ischaemic injuries [3]. Many animal experiments and 
clinical studies have shown that hypothermia can suppress 
these harmful inﬂ ammatory reactions, and block the 
release of proinﬂ ammatory cytokines [5-8]. Hypothermia 
can also decrease produc tion of leuko trienes and nitric 
oxide, prevent reperfusion-related DNA injury and lipid 
peroxidation, and impair neutrophil and macrophage 
function. At temperatures <32 to 33°C, hypothermia can 
decrease the white blood cell count [2,3].
Th e proinﬂ ammatory response, however, is not purely 
harmful. Some reactions are helpful in tissue repair, and 
the good may be inhibited along with the bad [9-12]. 
Moreover, suppression of inﬂ ammatory responses occurs 
in all organs, not just the injured ones, and inhibition of 
immune response can lead to an increased risk of infec-
tions. In this sense, hypothermia is a two-edged sword: 
the mechanism that provides tissue protection can simul-
taneously hamper the bodies’ ability to ﬁ ght infections. 
Th is problem can be compounded by hypothermia-
associated hyperglycaemia, which can further increase 
the infection risks [3].
Many clinical studies have indeed found higher infec-
tion rates in patients treated with prolonged (>24 hours) 
therapeutic cooling [4]. For example, in a recently 
published study in patients with ischaemic stroke, the 
rate of pneumonia was 50% in patients treated with 
hypothermia versus 10% in controls. Nevertheless, out-
comes were better in the hypothermia group, in spite of 
these adverse events [13]. Most studies on therapeutic 
cooling have reported trends or signiﬁ cantly higher 
infection rates in patients treated with cooling, with the 
risks appearing to increase with longer treatment periods 
[4]. Th e increase in infection risk may be even greater 
with accidental hypothermia [14].
Based on the physiological data and the clinical studies 
discussed above, some increase in infection risk is usually 
regarded as an unavoidable consequence of hypothermia 
treatment. Duration of cooling therapy is often limited 
because of the (perceived) risk of infections. Few of the 
clinical trials performed so far, however, have used 
standard decontamination of the digestive tract (SDD) or 
other forms of antibiotic prophylaxis in their patients.
Abstract
In vitro studies and clinical observations suggest 
that both accidental and controlled/therapeutic 
hypothermia have a strong immunosuppressive eff ect, 
and that hypothermia increases the risk of infections, 
especially wound infections and pneumonia. In the 
previous issue of Critical Care, Kamps and colleagues 
report that when hypothermia was used for prolonged 
periods in patients with severe traumatic brain injury 
in conjunction with selective decontamination of 
the digestive tract, the risks of infection were the 
same or lower in patients treated with therapeutic 
cooling. The risk of infection is widely regarded as 
the most important danger of therapeutic cooling. 
The fi ndings of Kamps and colleagues need to be 
verifi ed in prospective trials and in higher-resistance 
environments, but raise the possibility of cooling for 
prolonged periods with greatly reduced risk. We may 
be able to have our cake and eat it.
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In the previous issue of Critical Care, Kamps and 
coworkers report on their use of prolonged therapeutic 
cooling to control intracranial pressure in patients with 
severe traumatic brain injury, in a setting where SDD was 
routinely used [1]. Th ey compared infection rates in 35 
patients treated with hypothermia (median duration 
107  hours) with 169 controls matched for severity of 
injury, age, and other relevant factors. SDD was used in 
all patients. Th e overall risk of any infection was 20% for 
hypothermia patients, versus 34.4% in controls. Most 
notably, the risk of ventilator-associated pneumonia was 
the same in patients treated with hypothermia compared 
with matched controls.
Th ese ﬁ ndings may come as a surprise, but they are in 
line with two previous studies using prolonged hypo-
thermia in combination with SDD [15,16]. Th ese studies 
also reported low infection rates in patients treated with 
hypothermia and SDD, and found that infection rates 
were the same or lower than in controls.
Many studies have shown that SDD can reduce Gram-
negative infection rates, and some have reported reduc-
tions in intensive care unit mortality [17]. Th e ﬁ ndings of 
Kamps and colleagues suggest that SDD could help avoid 
one of the most important complications of therapeutic 
cooling. Th eir ﬁ nd ings need to be conﬁ rmed in larger, 
prospective studies, and the eﬃ  cacy of SDD in 
environments with a higher incidence of resistant micro-
organisms needs to be determined. Th e study by Kamps 
and colleagues provides an exciting starting point, and 
opens up possibilities for exploring long-term hypo ther-
mia treatments.
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